AbCheck s.r.o. Achieves First Milestone In Pierre Fabre Partnership

PLZEN, Czech Republic--(BUSINESS WIRE)--AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, announced today the achievement of a first milestone in its strategic partnership with Pierre Fabre Pharmaceuticals of Castres, France. The milestone represents confirmation of in vivo activity for at least one antibody discovered by AbCheck under the collaboration agreement and triggers an undisclosed milestone payment from Pierre Fabre.

“We have recently added a novel mass humanization technology to our established technologies, which include the proprietary AbSieve and AbAccel platforms.”

AbCheck, a wholly owned subsidiary of Affimed, Heidelberg, Germany, recognized throughout the US and Europe for its expertise in discovering and optimizing human antibodies and Pierre Fabre, France’s third-largest pharmaceutical company with a long-standing commitment to oncology and immunology, entered into a development collaboration in 2014. This collaboration was expanded into a strategic partnership in June 2015. Under the ongoing agreement, AbCheck uses its proprietary human antibody discovery platform and optimization technologies to deliver antibodies against Pierre Fabre’s targets.

“Reaching this first milestone for Pierre Fabre proves the effectiveness of our technology platforms for the efficient discovery of high-quality antibodies,” said Dr. Volker Lang, Managing Director of AbCheck. “We have recently added a novel mass humanization technology to our established technologies, which include the proprietary AbSieve and AbAccel platforms.”

About AbCheck

AbCheck discovers and optimizes human antibodies leveraging several proprietary platforms including in vitro and in vivo technologies. We use phage/yeast display libraries (AbSieve), mass humanization and antibody optimization (AbAccel) to provide high quality leads. Our technology platform can be used in conjunction with all antibody designs and allows selection of optimized leads from a huge number of variants. Flexibly adapting to our partner’s needs, we offer a variety of business models, including deals without royalties. AbCheck has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH.